跳至主要内容
临床试验/NL-OMON41245
NL-OMON41245已完成4 期

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis - M13-375 Spondyloarthritis study

AbbVie B.V.0 个研究点目标入组 54 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
AbbVie B.V.
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Main Inclusion: ;- Adult subjects with inadequate response of 2 or more non-steroidal anti-inflammatories (NSAIDs);- Subject with axial SpA fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axial SpA classification criteria ;- Subject with evidence of active inflammation in the SI joints or spine on MRI, or elevated hs-CRP;- Negative purified protein derivative (PPD) test and Chest X-Ray performed at Baseline Visit must be Negative;- Negative TB screening assessment;- Ability to administer subcutaneous injections;- General good health otherwise

排除标准

  • Main Exclusion: ;- Prior anti-TNF therapy;- Fulfillment of modified New York criteria for Ankylosing Spondylitis;- Recent infection requiring treatment;- Significant medical events or conditions that may put patients at risk for participation;- Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;- History of cancer, except successfully treated skin cancer;- Recent history of drug or alcohol abuse

研究者

发起方
AbbVie B.V.

相似试验

进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis
EUCTR2012-000646-35-BEAbbVie Deutschland GmbH & Co. KG740
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial SpondyloarthritisAxial SpondyloarthritisMedDRA version: 14.1Level: LLTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 100000004859
EUCTR2012-000646-35-ITAbbVie Deutschland GmbH & Co. KG673
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial SpondyloarthritisAxial SpondyloarthritisMedDRA version: 18.0Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2012-000646-35-DKAbbVie Deutschland GmbH & Co. KG740
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial SpondyloarthritisAxial SpondyloarthritisMedDRA version: 17.1Level: LLTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 100000004859
EUCTR2012-000646-35-PLAbbVie Deutschland GmbH & Co. KG740
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial SpondyloarthritisAxial SpondyloarthritisMedDRA version: 19.0 Level: PT Classification code 10071400 Term: Axial spondyloarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2012-000646-35-DEAbbVie Deutschland GmbH & Co. KG673